GlassScriptPhysician profile
Rachel Bass
NPI 1699185280
$329.95
in general payments reported to CMS, 2019-2025
9 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
See the full distribution for Neuromuscular Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.54 · 2022: $19.17 · 2023: $100 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $77.80 | 2025 | Evrysdi |
| Catalyst Pharmaceuticals, INC. | $75.09 | 2023 | Firdapse |
| Genentech USA, INC. | $40.54 | 2019 | |
| Biogen, INC. | $25.16 | 2023 | Spinraza |
| Novartis Pharmaceuticals Corporation | $24.99 | 2025 | |
| Ucb, INC. | $24.33 | 2025 | Fintepla |
| Otter Pharmaceuticals, LLC | $22.41 | 2025 | Sympazan |
| Teva Pharmaceuticals USA, INC. | $20.46 | 2025 | Ajovy |
| Xeris Pharmaceuticals, INC. | $19.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Bass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.